NHLBI SBIR Phase IIB Bridge Awards

NHLBI SBIR Phase IIB Bridge Awards are the institute's late-stage follow-on awards for companies that have already completed an SBIR or STTR Phase II project. They support heart, lung, blood, and sleep technologies as they move beyond development and toward regulatory clearance and commercialization. The program uses the R44 activity code and can provide up to $3.5 million over three years. It is limited to US for-profit applicants and requires a prior Phase II award. Applications are annual, with the cycle anchored in February, and the current opportunity cap in the record is tied to NHLBI's dedicated funding commitment across FY2026 through FY2030. This is a strong fit for companies with a real product, a remaining translational gap, and enough prior data to justify a bigger push toward market entry. The program is not for first-time applicants or earlier-stage feasibility work; it rewards teams that already have Phase II traction and can show why additional capital will move the technology toward clearance and adoption.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.